Citigroup Inc Keros Therapeutics, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 117,456 shares of KROS stock, worth $5.37 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

117,456

Previous 169,391 30.66%

Holding current value

$5.37 Million

Previous $6.73 Million 15.46%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$41.26 - $70.48 $2.14 Million - $3.66 Million	-51,935 Reduced 30.66%	117,456 $7.78 Million
Q4 2023 Feb 09, 2024	BUY	$27.12 - $41.05 $1.93 Million - $2.93 Million	71,282 Added 72.66%	169,391 $6.73 Million
Q3 2023 Nov 09, 2023	SELL	$31.57 - $43.02 $1.73 Million - $2.35 Million	-54,738 Reduced 35.81%	98,109 $3.13 Million
Q2 2023 Aug 10, 2023	SELL	$37.26 - $51.01 $6.45 Million - $8.84 Million	-173,217 Reduced 53.12%	152,847 $6.14 Million
Q1 2023 May 11, 2023	SELL	$41.44 - $59.32 $3.57 Million - $5.1 Million	-86,039 Reduced 20.88%	326,064 $13.9 Million

Q4 2022 Feb 09, 2023	SELL	$39.45 - $51.77 $2.53 Million - $3.31 Million	-64,020 Reduced 13.45%	412,103 $19.8 Million
Q3 2022 Nov 10, 2022	BUY	$27.8 - $40.12 $382,333 - $551,770	13,753 Added 2.97%	476,123 $17.9 Million
Q2 2022 Aug 10, 2022	BUY	$26.03 - $67.04 $11.8 Million - $30.5 Million	454,498 Added 5773.6%	462,370 $12.8 Million
Q1 2022 May 12, 2022	SELL	$42.12 - $59.36 $1.02 Million - $1.44 Million	-24,248 Reduced 75.49%	7,872 $428,000
Q4 2021 Feb 10, 2022	BUY	$36.95 - $62.89 $499,490 - $850,147	13,518 Added 72.67%	32,120 $1.88 Million
Q3 2021 Nov 10, 2021	BUY	$29.27 - $43.71 $544,480 - $813,093	18,602 New	18,602 $736,000

Others Institutions Holding KROS

# of Institutions

153

Shares Held

26.7M

Call Options Held

47.6K

Put Options Held

34.5K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account